New scan may tell rectal cancer patients if they can skip surgery

NCT ID NCT06608537

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This completed phase 2 study tested whether a new type of PET scan (FAPI-PET/CT) can accurately predict if rectal cancer has completely disappeared after a combination of short-course radiation, immunotherapy, and chemotherapy. Fifty-two patients with locally advanced rectal cancer received the treatment and then underwent both standard FDG-PET and FAPI-PET scans before surgery. The goal was to see if the FAPI scan could reliably identify patients who achieved a pathological complete response, potentially allowing them to avoid surgery and preserve their rectum.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
18F-FAPI-42 radiotracer (for PET/CT imaging)
What this could lead to
If successful, this imaging method could help doctors accurately identify which rectal cancer patients have a complete response to treatment, allowing more patients to avoid surgery and preserve their rectum.
What could go wrong
This is a small, single-center phase 2 study with only 52 participants, so results may not apply to all patients. The imaging technique is still experimental and not yet standard practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Department of colorectal surgery, the Sixth Affiliated Hospital, Sun Yat-Sen University

    Guangzhou, Guangdong, 510000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.